This event is sponsored by Sanofi. MAT-US-2309138-v1.0-10/2023
Recently, CEACAM5 is emerging as a potential biomarker of investigation in advanced NSq NSCLC.
Our latest Lab Talk with Dr. Sameer Talwalkar, MD, FCAP, explores CEACAM5 as a potential biomarker in advanced NSq (non-squamous) NSCLC (non-small cell lung cancer). In this session Dr. Talwalkar will discuss the biomarker testing landscape in NSCLC including a deep dive into CEACAM5 as a potential biomarker.
CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) is currently being explored as a potential biomarker in advanced NSq (non-squamous) NSCLC (non-small cell lung cancer). Early investigational studies have shown high CEACAM5 expression in ~25% of advanced NSq NSCLC. CEACAM5 has higher differential expression in a subset of NSCLC tumors vs healthy lung tissue. Understanding CEACAM5 may potentially give more insights to target this malignancy which may have a poor prognosis.
Speaker name: Dr. Sameer Talwalkar
Dr. Talwalkar is a board certified Hematopathologist and Molecular Pathologist at CPA Lab, Norton Healthcare, Louisville, KY. Dr. Talwalkar joined CPA lab in 2009 and was instrumental in starting the molecular diagnostics lab which is currently the only CAP accredited and CLIA certified lab in Louisville serving the oncology patients at Norton Cancer Institute. Dr. Talwalkar received his medical degree from the University of Mumbai, followed by residency training at the University of Louisville, Hematopathology fellowship at UT MD Anderson Cancer Center and Molecular Genetic pathology fellowship at the University of Pittsburgh. Dr. Talwalkar has presented numerous abstracts and authored several peer-reviewed publications in national and international journals. His interests include oncology focused biomarker discovery, spatial biology of tumors and their microenvironment and use of digital pathology and AI based tools for tumor identification and grading.